MedTrace Logo

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

NCT01832766 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2015-09-21

Study results available
· View outcomes & findings →

Summary

Approximately 25% of people with schizophrenia abuse marijuana. These people may be using marijuana to self-medicate symptoms such as hallucinations (hearing or seeing things that are not heard or seen by others) or delusions (false beliefs i.e. people are harassing or persecuting them) or the depressed and anxious feelings brought on by these symptoms. Currently, it is unknown whether marijuana makes schizophrenia better or worse. Marijuana intoxication in people without schizophrenia generally causes decreased recall of words, may decrease reaction time and decrease inhibition. Additionally, marijuana may cause distractibility as demonstrated by difficulty keeping their eyes on a moving target and difficulty inhibiting their response to repetitive tones. However, marijuana may have different effects in schizophrenia. Receptors for cannabis (marijuana) are concentrated in the brain and maladjustment of the cannabinoid system may be associated with the difficulty in thinking found in schizophrenia. The proposed research project examines if clinical symptoms, learning, memory, inhibition and distractibility are improved or made worse by the acute ingestion of tetrahydrocannabinol (THC).

Conditions

Interventions

DRUG

Dronabinol

dronabinol 10 mg one capsule by mouth at 8:00 a.m.

OTHER

Placebo Comparator

one capsule given by mouth at 8:00 a.m.

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Lynn Johnson, Pharm D · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2010-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01832766 on ClinicalTrials.gov